Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
The ruling weakens Yutrepia’s prospects and sent Liquidia shares down nearly 50%, while a final judgment is expected in about a week, analysts said.
- On Wednesday, a U.S. District Court in Delaware ruled that Liquidia Corporation's drug Yutrepia infringes two foundational claims of a patent held by rival United Therapeutics Corporation, dealing a major blow to the treatment's commercial outlook.
- The ruling followed Liquidia's prior concession that Yutrepia infringes claims 1 and 14 of the 11,826,327 patent, which covers inhaled treprostinil treatments for pulmonary hypertension associated with interstitial lung disease.
- Shares of Liquidia collapsed 57% on Wednesday, erasing about $3.18 billion in market value, while United Therapeutics shares surged 13% as investors reacted to the patent validation.
- CEO Roger Jeffs said, "We respectfully disagree with the court's decision," and the company plans to ask the FDA to remove the PH-ILD indication from Yutrepia's label.
- Within one week, the court will determine remedies, including potential injunctive relief that "would restrict YUTREPIA's availability." Analysts warn the ruling "significantly clouds the path" for the drug's competition.
11 Articles
11 Articles
24/7 Wall St.
BizTocUnited Therapeutics Won Its Patent War and Liquidia Collapsed
A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting for survival, but the legal battle over Yutrepia's future is far from settled.
Liquidia slumps after US court rules for United Therapeutics in patent fight
Sept 30 (Reuters) - Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by rival United Therapeutics, dealing a major blow to the treatment's commercial outlook. The US District Cou...
Hastings Tribune
Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
District Court ruled that two of the six claims asserted against Liquidia are valid and infringedParties directed to submit form of judgment, specifying the proposed remedy, for the District Court’s consideration within one week
Cash shares in vertical fall Wednesday, September 30: Liquidia Corporation (LQDA) lost 57.19% in a single session, closing at $30.26. The collapse follows the judgment of the Delaware District Court that recognized the violation of a patent of United Therapeutics on the drug YUTREPIA. A fundamental event that has rewritten the entire structure [...]
United Therapeutics Surges 13% After Patent Victory Against Liquidia
United Therapeutics shares rose nearly 13% Wednesday after a federal court ruled that rival Liquidia infringed two patent claims covering... The post United Therapeutics Surges 13% After Patent Victory Against Liquidia appeared first on citybiz.
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
